HIV

Gilead plans European trial of twice-yearly HIV PrEP drug
Gilead plans European trial of twice-yearly HIV PrEP drug
Pharmaphorum
Gilead Sciences
clinical trials
HIV
PrEP
Sunlenca
Europe
Flag link:
GSK dials up HIV sales projection to £7B by 2026, updates next-gen launch timelines
GSK dials up HIV sales projection to £7B by 2026, updates next-gen launch timelines
Fierce Pharma
GSK
HIV
Cabenuva
ViiV Healthcare
Flag link:
Gilead Sciences, after trial win, moves ahead with $247M settlement in HIV antitrust case
Gilead Sciences, after trial win, moves ahead with $247M settlement in HIV antitrust case
Fierce Pharma
Gilead Sciences
Teva Pharmaceutical
HIV
legal
antitrust
Flag link:
HIV Vaccine Trial of Vir Biotech’s New Candidate VIR-1388 Begins
HIV Vaccine Trial of Vir Biotech’s New Candidate VIR-1388 Begins
Xtalks
Vir Biotechnology
clinical trials
HIV
VIR-1388
Flag link:
ViiV Healthcare receives European Commission approval for Apretude
ViiV Healthcare receives European Commission approval for Apretude
Pharmaceutical Business Review
ViiV Healthcare
Europe
Apretude
HIV
AIDS
PrEP
Flag link:
FDA grants tentative approval for Viatris’ pediatric HIV drug
FDA grants tentative approval for Viatris’ pediatric HIV drug
Business Today
Viatris
FDA
HIV
pediatrics
abacavir
dolutegravir/lamivudine
Flag link:
Absci and Caltech receive grant from Bill and Melinda Gates Foundation for HIV vaccine effort
Absci and Caltech receive grant from Bill and Melinda Gates Foundation for HIV vaccine effort
Biopharma Reporter
Absci
Caltech
grants
HIV
artificial intelligence
Gates Foundation
vaccines
Flag link:
HIV cell therapy startup Addimmune heads to Wall Street via blank-check merger
HIV cell therapy startup Addimmune heads to Wall Street via blank-check merger
BioPharma Dive
Addimmune
HIV
SPAC
Flag link:
Gilead unveils $6 million HIV and viral hepatitis initiative for Australian and Canadian indigenous communities
Gilead unveils $6 million HIV and viral hepatitis initiative for Australian and Canadian indigenous communities
Biopharma Reporter
Gilead Sciences
HIV
Australia
Canada
indigenous communities
Flag link:
J&J, GSK's ViiV tout switching study showing patients prefer their long-acting HIV med Cabenuva over Gilead rival
J&J, GSK's ViiV tout switching study showing patients prefer their long-acting HIV med Cabenuva over Gilead rival
Fierce Pharma
JNJ
GSK
ViiV
Gilead Sciences
HIV
Cabenuva
Biktarvy
Flag link:
Statins reduce cardiovascular risk in people living with HIV, new global study finds
Statins reduce cardiovascular risk in people living with HIV, new global study finds
Stat
statins
HIV
cardiovascular disease
Flag link:
Janssen’s newly-merged infectious disease and vaccine unit sees significant pipeline cuts
Janssen’s newly-merged infectious disease and vaccine unit sees significant pipeline cuts
Fierce Biotech
JNJ
Janssen
infectious disease
vaccines
hepatitis
HIV
Flag link:
Medicare proposes coverage for PrEP without patient cost sharing
Medicare proposes coverage for PrEP without patient cost sharing
Fierce Healthcare
Medicare
CMS
HIV
PrEP
Flag link:
GSK's ViiV explores novel pathway to bring long-acting HIV med Cabenuva to tough-to-treat patients
GSK's ViiV explores novel pathway to bring long-acting HIV med Cabenuva to tough-to-treat patients
Fierce Pharma
GSK
ViiV Healthcare
HIV
Cabenuva
Flag link:
Gilead, Teva prevail in high-stakes trial over HIV drug pay-for-delay claims
Gilead, Teva prevail in high-stakes trial over HIV drug pay-for-delay claims
Fierce Pharma
Gilead Sciences
Teva Pharmaceutical
HIV
pay-for-delay
generics
legal
Flag link:
US appeal in high-stakes Gilead patent case garners support from patient advocates
US appeal in high-stakes Gilead patent case garners support from patient advocates
Fierce Pharma
Gilead Sciences
HIV
patents
legal
DOJ
Truvada
Flag link:
Gilead, Teva reach 11th-hour settlements with some groups in HIV antitrust case
Gilead, Teva reach 11th-hour settlements with some groups in HIV antitrust case
Fierce Pharma
Gilead Sciences
Teva Pharmaceutical
HIV
legal
antitrust
Flag link:
After years of litigation, Gilead and Teva's HIV antitrust trial kicks off in California
After years of litigation, Gilead and Teva's HIV antitrust trial kicks off in California
Fierce Pharma
Gilead Sciences
Teva Pharmaceutical
legal
HIV
antitrust
Flag link:
Gilead notches trial win in high-stakes HIV patent case against US government
Gilead notches trial win in high-stakes HIV patent case against US government
Fierce Pharma
Gilead Sciences
Truvada
HIV
Descovy
legal
patents
Flag link:
Vir Biotechnology awarded $10 million grant by Bill & Melinda Gates Foundation to develop HIV vaccine
Vir Biotechnology awarded $10 million grant by Bill & Melinda Gates Foundation to develop HIV vaccine
Biopharma Reporter
Vir Biotechnology
Gates Foundation
vaccines
HIV
Flag link:

Pages